- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04062266
AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission
Phase II Study of 5-Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remission
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To assess relapse-free survival (RFS) of patients (pts) with acute myeloid leukemia (AML) treated with 5-azacytidine (azacitidine; AZA) combined with venetoclax (VEN) as maintenance therapy after achieving remission.
SECONDARY OBJECTIVES:
I. To assess modified RFS of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.
II. To assess overall survival (OS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.
III. To assess event-free survival (EFS) of pts with AML treated with 5-azacytidine combined with venetoclax as maintenance therapy.
IV. To assess the duration of remission (CRd) of pts with AML treated 5-azacytidine combined with venetoclax as maintenance therapy.
V. To assess toxicity and safety of 5-azacytidine combined with venetoclax as maintenance therapy in pts with AML.
VI. To assess the effects of 5-azacytidine combined with venetoclax on dynamics of minimal residual disease (MRD) and their relationship to outcomes.
OUTLINE:
Patients receive azacitidine subcutaneously (SC) or intravenously (IV) over 1 hour daily on days 1-5, and venetoclax orally (PO) daily on days 1-14. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 6-12 months thereafter.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tapan M. Kadia
- Phone Number: 713-563-3534
- Email: tkadia@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Principal Investigator:
- Tapan M. Kadia
-
Contact:
- Tapan M. Kadia
- Phone Number: 713-563-3534
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged >/= 18 years AML who have achieved their FIRST CR or CRi and are not immediately candidates for allogeneic stem cell transplant.
- Patients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be enrolled in COHORT 1.
- Patients who have received lower intensity therapy (defined as receiving low-dose cytarabine (LDAC) or hypomethylating agent (HMA)-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be treated on COHORT 2.
- For either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement.
- ECOG performance status of < or = 3
Adequate organ function as follows:
- Serum total bilirubin < or = to 1.5 X the Upper Limit of Normal (ULN)
- Serum creatinine < or = to 2.5 x ULN
Adequate BM reserve:
- Absolute neutrophil count (ANC) > 0.5 x k/uL
- Platelet count > or = 30 x k/uL
For females of childbearing age, they may participate if they:
- Have a negative serum or urine pregnancy test within 10 to 14 days of enrolling
- Agree to either abstinence or 2 effective contraceptive methods (such as barrier methods or hormonal contraception) throughout the treatment period and up to 30 days after discontinuing treatment.
- For male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment.
- Ability to understand and sign informed consent.
Exclusion Criteria:
- Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by FAB classification based on morphology, immunophenotype, molecular, or cytogenetic s studies.
- Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor.
- Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with active CNS (central nervous system) disease.
- Patients with documented hypersensitivity to any components of the study program.
- Females who are pregnant or lactating or intending to become pregnant during the study.
- Patients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment.
- Patient should be removed from current trial if they wish to participate and get treatment on another trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (azacytidine, venetoclax)
Patients receive azacitidine SC or IV over 1 hour daily on days 1-5, and venetoclax PO daily on days 1-14.
Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
|
Given SC or IV
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse-free survival (RFS)
Time Frame: From date of complete remission (CR) or complete remission with incomplete count recovery (CRi), assessed for up to 10 years
|
The study will be continuously monitored for the primary endpoint, RFS, using the method of Thall, Wooten, and Tannir (2005).
Will also summarize the posterior distribution of lambda-E (i.e., median RFS) assuming posterior mean and 95% credible interval.
|
From date of complete remission (CR) or complete remission with incomplete count recovery (CRi), assessed for up to 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of toxicity
Time Frame: Up to 10 years
|
Toxicities are defined as any treatment -related clinically significant grade 3 or 4 non-hematologic adverse events occurred during cycles 1-2 of the trial.
Will continuously monitor treatment-related toxicities using the Bayesian approach of Thall, Simon, Estey (1995).
|
Up to 10 years
|
Modified RFS
Time Frame: Time from enrollment on study until date of first objective documentation of relapse or death, assessed for up to 10 years
|
Distribution assessed using Kaplan-Meier method.
|
Time from enrollment on study until date of first objective documentation of relapse or death, assessed for up to 10 years
|
Overall survival (OS)
Time Frame: From the start of study treatment until date of death due to any cause, assessed for up to 10 years
|
Distribution assessed using Kaplan-Meier method.
|
From the start of study treatment until date of death due to any cause, assessed for up to 10 years
|
Event free survival (EFS)
Time Frame: From the start of study treatment until date of first confirmed relapse, withdrawal from study due to adverse event, or death due to any cause, assessed for up to 10 years
|
Distribution assessed using Kaplan-Meier method.
|
From the start of study treatment until date of first confirmed relapse, withdrawal from study due to adverse event, or death due to any cause, assessed for up to 10 years
|
Complete remission duration (CRd)
Time Frame: Time from CR or CRi until date of first objective documentation of confirmed relapse, assessed for up to 10 years
|
Distribution assessed using Kaplan-Meier method.
|
Time from CR or CRi until date of first objective documentation of confirmed relapse, assessed for up to 10 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tapan M Kadia, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Neoplastic Processes
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Hematologic Diseases
- Neoplasm, Residual
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Venetoclax
- Azacitidine
Other Study ID Numbers
- 2019-0226 (Other Identifier: M D Anderson Cancer Center)
- NCI-2019-04987 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
Clinical Trials on Azacitidine
-
Shandong Provincial HospitalUnknownMyelodysplastic Syndromes,Acute Myeloid LeukemiaChina
-
TJ Biopharma Co., Ltd.Recruiting
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Celgene CorporationCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)Australia
-
Eisai Inc.TerminatedMyelodysplastic SyndromesUnited States
-
Navy General Hospital, BeijingRecruitingRefractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin LymphomaChina
-
University of BirminghamRecruitingAcute Myeloid Leukemia | MyelodysplasiaUnited Kingdom
-
Nanexa ABUppsala UniversityCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)Sweden
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
Bristol-Myers SquibbRecruitingMyelodysplastic SyndromesUnited States, Japan, Argentina, Hong Kong, Greece, Italy, China, Australia, Spain, Austria, Denmark, Germany, Sweden, Switzerland, Canada, Czechia, Korea, Republic of, Poland, Turkey, France
-
CelgeneCompletedMyelodysplastic SyndromesUnited States